Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

NRXP

+ Watchlist+ Portfolio

NRX Pharmaceuticals, Inc.

Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$2.45
52-Week Range
$1.62 – $5.06
Market Cap
$124.12M
P/E (TTM)
—
EPS (TTM)
-0.33
Dividend Yield
0.00%
Advanced Metrics
Price/Book
—
PEG Ratio
—
Return on Equity
—
Return on Assets
-70.06%
Gross Margin
39.97%
Operating Margin
-556.55%
Profit Margin
0.00%
Current Ratio
0.76
Debt/Equity
—
Total Debt
$978.00K
Free Cash Flow
$-14.58M
Revenue Growth
378.90%
Earnings Growth
—
Enterprise Value
$105.27M

Market Snapshot

About

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for pain management and psychiatric disorders. The company focuses on NMDA receptor antagonists and other neurological targets to treat conditions including post-traumatic stress disorder and chronic pain. NRX is advancing multiple drug candidates through clinical trials and regulatory pathways.